CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
|
12 Months Ended |
Dec. 31, 2021 |
Dec. 31, 2020 |
| Cash Flows from Operating Activities: |
|
|
| Net Gain/(Loss) |
$ (1,987,122)
|
$ (2,576,375)
|
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
| Depreciation and amortization |
5,100
|
9,048
|
| Warrants issued for services |
608,836
|
|
| Non-cash compensation |
|
|
| Change in fair value on derivative liability |
85,325
|
(1,053,186)
|
| Loss on extinguishment of debt |
|
(46,836)
|
| Gain on sale of asset |
|
|
| Impairment of goodwill |
|
1,579,883
|
| Changes in operating assets and liabilities: |
|
|
| Accounts receivable |
(120,066)
|
13,199
|
| Inventory |
459,717
|
663,476
|
| Accrued interest receivable |
|
|
| Accounts payable |
(27,569)
|
43,711
|
| Accounts payable - related party |
|
|
| Accrued liabilities |
50,210
|
(44,287)
|
| Accrued interest payable |
10,671
|
(47,524)
|
| Accrued interest payable - related party |
13,600
|
(490,703)
|
| Net Cash used in Operating Activities |
(901,298)
|
(1,902,758)
|
| Cash Flows from Investing Activities: |
|
|
| Purchase of fixed assets |
|
|
| Cash received from sale of asset |
|
|
| Purchase of note receivable |
|
|
| Trademarks |
(96,004)
|
(115,740)
|
| Payments of note receivable |
|
|
| Cash flows provided by (used in) Investing Activities: |
(96,004)
|
(115,740)
|
| Cash Flows from Financing Activities: |
|
|
| Purchase of BergaMet |
|
|
| Purchase of UBN |
|
|
| Proceeds from issuance of common stock |
995,199
|
4,405,791
|
| Proceeds from issuance of convertible debt, |
165,000
|
(1,501,876)
|
| Payments for repayment of convertible debt |
|
|
| Proceeds from issuance of noted payable |
|
(79,667)
|
| Proceeds from issuance of noted payable - related party |
|
(880,000)
|
| Payments for repayment of notes payable - related party |
|
|
| Net Cash provided by Financing Activities |
1,160,199
|
1,944,248
|
| Increase (decrease) in cash |
162,897
|
(74,250)
|
| Cash at beginning of period |
59,201
|
133,451
|
| Cash at end of period |
$ 222,098
|
$ 59,201
|